Is BPC-157 legal in the US?
A remote visit, a prescription decision and a pharmacy ingredient rule answer different questions. The word legal has to carry all that detail.
A visit cannot settle the ingredient question
A clinician can consider BPC-157 prescription care after an individual assessment. That decision is separate from FDA approval of a drug and from a pharmacy's eligibility to use a bulk ingredient. The 503A interim guidance describes the patient-specific compounding framework; the FDA bulk-substance page sets out the ingredient requirements.
For a local pharmacy under section 503A, the bulk substance must meet an applicable official U.S. quality standard, be a component of an FDA-approved drug, or appear on the FDA's 503A Bulks List, as the framework requires. A valid prescription does not by itself satisfy those ingredient requirements. Section 503B outsourcing facilities operate under a separate framework.
I resist a one-word answer because it hides which decision is being discussed. A phone or video assessment changes the setting of the conversation while leaving the pharmacy's ingredient rules in place. These are general regulatory facts, not legal or medical advice.
Withdrawn nominations still carry the safety concerns
BPC-157 is not an FDA-approved drug. On September 29, 2023, FDA placed it in Category 2, the group for substances with significant safety concerns. FDA lists BPC-157 among “Bulk drug substances nominated but withdrawn” after its nominators withdrew their requests; withdrawal alone grants no permission to compound, and the FDA's stated safety concerns remain.
Withdrawal of a nomination alone grants no permission to compound and does not establish Category 1 status.
The concerns include potential immune reactions, peptide-related impurities and difficulties characterizing the active ingredient. A tidy product description cannot answer those questions. I distrust a regulatory victory story when the safety text still occupies its page.
The January 7, 2025 interim-policy update stopped accepting new substances into the interim categories. Category 1 and Category 2 described different enforcement policies during evaluation; Category 2 had no assurance of interim enforcement discretion. Neither category meant FDA drug approval.
BPC-157 on the compounding advisory agenda
The July 23-24, 2026 Pharmacy Compounding Advisory Committee agenda lists BPC-157 free base and acetate. The question was whether a local pharmacy could use either form to prepare one patient's medicine, and FDA staff had recommended against it.
Committee members advise FDA. The cited agenda does not establish a final listing decision or permission to compound. I trust an agenda to establish its topics; a place on the list cannot establish the final result.
How can a pharmacy make medicine for one patient?
A doctor examines one patient and writes a valid prescription for medicine made to fit that person's need [14]. A licensed local pharmacy can prepare an allowed drug for that named patient [14]. Larger FDA-registered plants follow another set of rules and can supply some drugs to medical offices [14].
A video or phone visit can be the doctor's exam. The visit can't widen the list of raw drugs a pharmacy may use. The doctor must truly assess you, and the prescription must name you [14].
For one patient, the raw ingredient still has to be on a list allowed by the FDA, meet an accepted quality rule, or already be used in an approved drug. If none applies, the pharmacy can't use it. A remote visit doesn't change that.
For BPC-157, Promise Peptides provides prescription-only care at mypromise.com and prescribes after assessment by a licensed U.S. clinician, who may refuse the request. Only patients in the U.S. enter that process, and the state plus the treatment set its limits. The compounded medicine has no FDA approval. The FDA placed BPC-157 in Category 2, the safety-concern group, in 2023 [12]. The withdrawn nomination is not an authorization to compound; FDA safety concerns still apply to the ingredient [11][12].
These are the current rules in plain words. They can't replace advice from your doctor or lawyer, and nothing here is offered for supply.
Sport has its own answer
The musculoskeletal review discusses BPC-157’s prohibition in sport under WADA’s non-approved-substances category. It is prohibited at all times under that rule. A prescription discussion does not erase the sporting prohibition.
Drug-test questions are narrower again: these sources do not establish what a particular workplace or military test checks. The FAQ leaves that uncertainty intact. BPC-157's approval status, compounding requirements and sporting rules cannot substitute for one another.